Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press84410.17650/1726-9776-2018-14-3-43-50DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыPOSTOPERATIVE COMPLICATIONS OF MINIMALLY INVASIVE THERAPIES FOR PROSTATE CANCERПОСЛЕОПЕРАЦИОННЫЕ ОСЛОЖНЕНИЯ МАЛОИНВАЗИВНЫХ МЕТОДОВ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫhttps://orcid.org/0000-0001-7169-2209EnikeevD. V.ЕникеевД. В.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

RapoportL. M.РапопортЛ. М.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

Рапопорт Леонид Михайлович - заместитель директора НИИ уронефрологии и репродуктивного развития человека Первого МГМУ им. И.М. Сеченова, доктор медицинских наук, профессор.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

marktaratkin@gmail.comAmosovA. V.АмосовА. В.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

EnikeevM. E.ЕникеевМ. Э.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

ChinenovD. V.ЧиненовД. В.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

SnurnitsynaO. V.СнурницынаО. В.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

GerasimovA. N.ГерасимовА. Н.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

DzhalaevZ. K.ДжалаевЗ. К.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

GaasM. Ya.ГаасМ. Я.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

LaukhtinaE. A.ЛаухтинаЕ. А.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

https://orcid.org/0000-0003-4369-173XTaratkinM. S.ТараткинМ. С.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119991.

Тараткин Марк Сергеевич - младший научный сотрудник НИИ Уронефрологии.

119991 Москва, ул. Большая Пироговская, 2, стр. 1.

marktaratkin@gmail.comInsitute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaИнститут урологии и репродуктивного здоровья человека ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава РоссииDepartment of Medical Informatics and Statistics, I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaКафедра медицинской информатики и статистики ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России3009201814343502606201802072018https://oncourology.abvpress.ru/oncur/article/view/844

Prostate cancer is the most common cancer among men. Radical prostatectomy (open, laparoscopic, or robotic) remains the main method of surgical treatment for prostate cancer. However, minimally invasive therapies for prostate cancer are becoming increasingly popular in recent years, because they have similar efficacy as open surgery. The most studied minimally invasive therapies are cryoablation, high intensity focused ultrasound (HIFU), and brachytherapy.

Despite the minimization of damage to neighboring structures, minimally invasive procedures can cause a number of complications, like any other surgical interventions. Each method has specific limitations and the most typical complications. Since multiple minimally invasive methods are currently available, we can ensure an individual approach to each particular patient, thus using the advantages of the methods and avoiding possible complications. This article covers the most frequent and severe complications of minimally invasive therapies for prostate cancer, as well as the methods of their prevention and treatment.

Рак предстательной железы (РПЖ) является наиболее распространенным онкологическим заболеванием среди мужчин. Радикальная простатэктомия (открытая, лапароскопическая, роботическая) считается основным хирургическим методом лечения РПЖ. Однако в последние годы все бόльшую популярность набирают малоинвазивные методы лечения РПЖ, которые не отстают по эффективности от радикальной операции (по данным последних исследований). К наиболее изученным малоинвазивным технологиям относятся криоаблация, HIFU-терапия (High Intensity Focused Ultrasound) и брахитерапия.

Несмотря на минимизацию повреждения соседних структур, малоинвазивные методы лечения РПЖ, как и любые другие хирургические вмешательства, могут приводить к развитию ряда осложнений. Для каждого из методов существуют определенные ограничения, а также наиболее характерные и вероятные осложнения. Благодаря существованию на сегодняшний день целого ряда малоинвазивных методов лечения РПЖ возможен индивидуальный подход к конкретному пациенту, что позволяет избежать нежелательных осложнений и использовать сильные стороны каждого из методов. В настоящей работе рассмотрены наиболее частые и тяжелые осложнения, возникающие после малоинвазивного лечения РПЖ, а также методы их профилактики и лечения.

prostate cancercryoablationbrachytherapyHIFU therapycomplicationablationminimally invasive therapyрак предстательной железыкриоаблациябрахитерапияHIFU-терапияосложнениеаблациямалоинвазивная терапияSiegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11–30. DOI: 10.3322/caac.21166. PMID: 23335087.Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11–30. DOI: 10.3322/caac.21166. PMID: 23335087.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30. PMID: 28055103. DOI: 10.3322/caac.21387.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30. PMID: 28055103. DOI: 10.3322/caac.21387.Bell K.J., Del Mar C., Wright G. et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer 2015;137(7):1749–57. DOI: 10.1002/ijc.29538. PMID: 25821151.Bell K.J., Del Mar C., Wright G. et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer 2015;137(7):1749–57. DOI: 10.1002/ijc.29538. PMID: 25821151.Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment. Eur Urol 2017;71(4):618–29. DOI: 10.1016/j.eururo.2016.08.003. PMID: 27568654.Ficarra V., Novara G., Artibani W. et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009;55(5):1037–63. DOI: 10.1016/j.eururo.2009.01.036. PMID: 19185977.Ficarra V., Novara G., Artibani W. et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009;55(5):1037–63. DOI: 10.1016/j.eururo.2009.01.036. PMID: 19185977.Coelho R.F., Rocco B., Patel M.B. et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 2010;24(12):2003–15. DOI: 10.1089/end.2010.0295. PMID: 20942686.Coelho R.F., Rocco B., Patel M.B. et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 2010;24(12):2003–15. DOI: 10.1089/end.2010.0295. PMID: 20942686.Marien A., Gill I., Ukimura O. et al. Target ablation-image-guided therapy in prostate cancer. Urol Onol 2014;32(6):912–23. DOI: 10.1016/j.urolonc.2013.10.014. PMID: 24411788.Coleman J.A., Scardino P.T. Targeted prostate cancer ablation: energy options. Curr Opin Urol 2013;23(2):123–8. DOI: 10.1097/MOU.0b013e32835d9e94. PMID: 23287462.Coleman J.A., Scardino P.T. Targeted prostate cancer ablation: energy options. Curr Opin Urol 2013;23(2):123–8. DOI: 10.1097/MOU.0b013e32835d9e94. PMID: 23287462.Rees J., Patel B., MacDonagh R., Persad R. Cryosurgery for prostate cancer. BJU Int 2004;93(6):710–4. DOI: 10.1111/j.1464-410X.2003.04746.x. PMID: 15049977.Han K.R., Belldegrun A.S. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int 2004;93(1):14–8. PMID: 14678360.Aus G. Current status of HIFU and cryotherapy in prostate cancer – a review. Eur Urol 2006;50(5):927–34. DOI: 10.1016/j.eururo.2006.07.011. PMID: 16971038.Cordeiro E.R., Cathelineau X., Thüroff S. et al. High-intensity focused ultra-sound (HIFU) for definitive treatment of prostate cancer. BJU Int 2012;110(9):1228–42. DOI: 10.1111/j.1464-410X.2012.11262.x. PMID: 22672199.Cordeiro E.R., Cathelineau X., Thüroff S. et al. High-intensity focused ultra-sound (HIFU) for definitive treatment of prostate cancer. BJU Int 2012;110(9):1228–42. DOI: 10.1111/j.1464-410X.2012.11262.x. PMID: 22672199.Clyne M. Prostate cancer: prostatic swelling and shift upon HIFU. Nat Rev Urol 2013;10(6):306. DOI: 10.1038/nrurol.2013.98. PMID: 23628808.Shoji S., Uchida T., Nakamoto M. et al. Prostate swelling and shift during high intensity focused ultrasound: implication for targeted focal therapy. J Urol 2013;190(4):1224–32. DOI: 10.1016/j.juro.2013.03.116. PMID: 23583532.Shoji S., Uchida T., Nakamoto M. et al. Prostate swelling and shift during high intensity focused ultrasound: implication for targeted focal therapy. J Urol 2013;190(4):1224–32. DOI: 10.1016/j.juro.2013.03.116. PMID: 23583532.Rebillard X., Soulié M., Chartier-Kastler E. et al. HIFU in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 2008;101(10):1205–13. DOI: 10.1111/j.1464-410X.2008.07504.x. PMID: 18325057.Rebillard X., Soulié M., Chartier-Kastler E. et al. HIFU in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 2008;101(10):1205–13. DOI: 10.1111/j.1464-410X.2008.07504.x. PMID: 18325057.De Bari B., Daidone A., Alongi F. Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. Crit Rev Oncol Hematol 2015;94(3):360–70. DOI: 10.1016/j.critrevonc.2015.02.003. PMID: 25819287.National Institute for Health and Care Excellence (NICE). Prostate Cancer: Diagnosis and Treatment. Full Guidance. CG58, 2008.National Institute for Health and Care Excellence (NICE). Prostate Cancer: Diagnosis and Treatment. Full Guidance. CG58, 2008.US Department of Health and Human Services: Agency for Healthcare Research and Quality. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer. Health Care Bulletin No. 13, 2008.US Department of Health and Human Services: Agency for Healthcare Research and Quality. Comparative Evaluation of Radiation Treatments for Clinically Localized Prostate Cancer: An Update, 2010.US Department of Health and Human Services: Agency for Healthcare Research and Quality. Comparative Evaluation of Radiation Treatments for Clinically Localized Prostate Cancer: An Update, 2010.Pisansky T.M., Hunt D., Gomella L.G. et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol 2015;33(4):332–9. DOI: 10.1200/JCO.2014.58.0662. PMID: 25534388.Pisansky T.M., Hunt D., Gomella L.G. et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol 2015;33(4):332–9. DOI: 10.1200/JCO.2014.58.0662. PMID: 25534388.Hinnen K.A., Battermann J.J., van Roermund J.G. et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010;76(5):1433–8. DOI: 10.1016/j.ijrobp.2009.03.049. PMID: 19540075.Hinnen K.A., Battermann J.J., van Roermund J.G. et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010;76(5):1433–8. DOI: 10.1016/j.ijrobp.2009.03.049. PMID: 19540075.Cornu J.N., Merlet B., Ciofu C. et al. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol 2011;59(1):148–54. DOI: 10.1016/j.eururo.2010.10.031. PMID: 21030144.Cornu J.N., Merlet B., Ciofu C. et al. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol 2011;59(1):148–54. DOI: 10.1016/j.eururo.2010.10.031. PMID: 21030144.Filocamo M.T., Li Marzi V., Del Popolo G. et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. Eur Urol 2007;51(6):1559–64. DOI: 10.1016/j.eururo.2006.08.005. PMID: 16942833.Filocamo M.T., Li Marzi V., Del Popolo G. et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. Eur Urol 2007;51(6):1559–64. DOI: 10.1016/j.eururo.2006.08.005. PMID: 16942833.Alan C., Eren A.E., Ersay A.R. et al. Efficacy of duloxetine in the early management of urinary continence after radical prostatectomy. Curr Urol 2015;8(1):43–8. DOI: 10.1159/000365688. PMID: 26195963.Geraerts I., Van Poppel H., Devoogdt N. et al. Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial. Eur Urol 2013;64(5):766–72. DOI: 10.1016/j.eururo.2013.01.013. PMID: 23357349.Geraerts I., Van Poppel H., Devoogdt N. et al. Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial. Eur Urol 2013;64(5):766–72. DOI: 10.1016/j.eururo.2013.01.013. PMID: 23357349.Campbell S.E., Glazener C.M., Hunter K.F. et al. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2012;1. DOI: 10.1002/14651858.CD001843.pub4. PMID: 22258946.Campbell S.E., Glazener C.M., Hunter K.F. et al. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2012;1. DOI: 10.1002/14651858.CD001843.pub4. PMID: 22258946.Schröder A., Abrams P., Andersson K.E. et al. Guidelines on urinary incontinence. In: EAU guidelines. European Association of Urology. Ed. A.G. Arnheim. Arnheim, the Netherlands, 2010. Pp. 11–28.Imamoglu M.A., Tuygun C., Bakirtas H. et al. The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. Eur Urol 2005;47(2):209–13. DOI: 10.1016/j.eururo.2004.08.019. PMID: 15661416.Secin F.P., Martínez-Salamanca J.I., Eilber K.S. Limited efficacy of permanent injectable agents in the treatment of stress urinary incontinence after radical prostatectomy. Arch Esp Urol 2005;58(5):431–6. PMID: 16078785.Secin F.P., Martínez-Salamanca J.I., Eilber K.S. Limited efficacy of permanent injectable agents in the treatment of stress urinary incontinence after radical prostatectomy. Arch Esp Urol 2005;58(5):431–6. PMID: 16078785.Bauer R.M., Soljanik I., Füllhase C. et al. Results of the Advance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology 2011;77(2):474–9. DOI: 10.1016/j.urology.2010.07.541. PMID: 21167563.Bauer R.M., Soljanik I., Füllhase C. et al. Results of the Advance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology 2011;77(2):474–9. DOI: 10.1016/j.urology.2010.07.541. PMID: 21167563.Cornu J.N., Sèbe P., Ciofu C. et al. Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. BJU Int 2011;108(2):236–40. DOI: 10.1111/j.1464-410X.2010.09765.x. PMID: 20955265.Silva L.A., Andriolo R.B., Atallah A.N., da Silva E.M. Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. Cochrane Database Syst Rev 2011;(4):CD008306. DOI: 10.1002/14651858.CD008306.pub2. PMID: 21491408.Herschorn S., Bruschini H., Comiter C. et al. Surgical treatment of stressincontinence in men. Neurourol Urodyn 2010;29(1):179–90. DOI: 10.1002/nau.20844. PMID: 20025026.Herschorn S., Bruschini H., Comiter C. et al. Surgical treatment of stressincontinence in men. Neurourol Urodyn 2010;29(1):179–90. DOI: 10.1002/nau.20844. PMID: 20025026.Ramsay C.R., Adewuyi T.E., Gray J. et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19(49):1–490. DOI: 10.3310/hta19490. PMID: 26140518.Ward J.F., Jones J.S. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012;109(11):1648–54. DOI: 10.1111/j.1464-410X.2011.10578.x. PMID: 22035200.Ward J.F., Jones J.S. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012;109(11):1648–54. DOI: 10.1111/j.1464-410X.2011.10578.x. PMID: 22035200.Ohashi T., Yorozu A., Toya K. et al. Predictive factors of acute urinary retention requiring catheterization following 125I prostate brachytherapy. Jpn J Clin Oncol 2006;36(5):285–9. DOI: 10.1093/jjco/hyl008. PMID: 16698803.Ohashi T., Yorozu A., Toya K. et al. Predictive factors of acute urinary retention requiring catheterization following 125I prostate brachytherapy. Jpn J Clin Oncol 2006;36(5):285–9. DOI: 10.1093/jjco/hyl008. PMID: 16698803.Bucci J., Morris W.J., Keyes M. et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;53(1):91–8. PMID: 12007946.Pellizzon A.C., Salvajoli J.V., Maia M.A. et al. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol 2004;171(3):1105–8. DOI: 10.1097/01.ju.0000113260.07979.d3. PMID: 14767280.Henderson A., Ismail A.K., Cunningham M. et al. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol (R Coll Radiol) 2004;16(2):95–104. PMID: 15074730.Martens C., Pond G., Webster D. et al. Relationship of the international prostate symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 2006;5(1):9–13. DOI: 10.1016/j.brachy.2005.12.002. PMID: 16563992.Allardice J.T., Standfield N.J., Wyatt A.P. Acute urinary retention: which catheter? Ann R Coll Surg Engl 1988;70(6):366–8. PMID: 3207328.Fitzpatrick J.M., Desgrandchamps F., Adjali K. et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU Int 2012;109(1):88–95. DOI: 10.1111/j.1464-410X.2011.10430.x. PMID: 22117624.Ahyai S.A., Gilling P., Kaplan S.A. et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010;58(3):384–97. DOI: 10.1016/j.eururo.2010.06.005. PMID: 20825758.Ahyai S.A., Gilling P., Kaplan S.A. et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010;58(3):384–97. DOI: 10.1016/j.eururo.2010.06.005. PMID: 20825758.Chi A.C., Han J., Gonzalez C.M. Urethral strictures and the cancer survivor Curr Opin Urol 2014;24(4):415–20. DOI: 10.1097/MOU.0000000000000070. PMID: 24809412.Rourke K., Kinnaird A., Zorn J. Observations and outcomes of urethroplasty for bulbomembranous stenosis after radiation therapy for prostate cancer. World J Urol 2016;34(3):377–82. DOI: 10.1007/s00345-015-1608-2. PMID: 26047655.Elliott S.P., Meng M.V., Elkin E.P. et al. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol 2007;178(2):529–34. DOI: 10.1016/j.juro.2007.03.126. PMID: 17570425.Elliott S.P., Meng M.V., Elkin E.P. et al. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol 2007;178(2):529–34. DOI: 10.1016/j.juro.2007.03.126. PMID: 17570425.Borboroglu P.G., Sands J.P., Roberts J.L et al. Risk factors for vesicourethral anastomotic stricture after radical prostatectomy. Urology 2000;56(1):96–100. PMID: 10869633.Borboroglu P.G., Sands J.P., Roberts J.L et al. Risk factors for vesicourethral anastomotic stricture after radical prostatectomy. Urology 2000;56(1):96–100. PMID: 10869633.Sandhu J.S., Gotto G.T., Herran L.A. et al. Age, obesity, medical comorbidities and surgical technique are predictive of symptomatic anastomotic strictures after contemporary radical prostatectomy. J Urol 2011;185(6):2148–52. DOI: 10.1016/j.juro.2011.02.003. PMID: 21496848.Sandhu J.S., Gotto G.T., Herran L.A. et al. Age, obesity, medical comorbidities and surgical technique are predictive of symptomatic anastomotic strictures after contemporary radical prostatectomy. J Urol 2011;185(6):2148–52. DOI: 10.1016/j.juro.2011.02.003. PMID: 21496848.Mundy A.R., Andrich D.E. Posterior urethral complications of the treatment of prostate cancer. BJU Int 2012;110(3):304–25. DOI: 10.1111/j.1464-410X.2011.10864.x. PMID: 22340079.Mundy A.R., Andrich D.E. Posterior urethral complications of the treatment of prostate cancer. BJU Int 2012;110(3):304–25. DOI: 10.1111/j.1464-410X.2011.10864.x. PMID: 22340079.Bryk D.J., Yamaguchi Y., Zhao L.C. Tissue transfer techniques in reconstructive urology. Korean J Urol 2015;56(7):478–86. DOI: 10.4111/kju.2015.56.7.478. PMID: 26175866.Meeks J.J., Erickson B.A., Granieri M.A. et al. Stricture recurrence after urethroplasty: a systematic review. J Urol 2009;182(4):1266–70. DOI: 10.1016/j.juro.2009.06.027. PMID: 19683309.Meeks J.J., Erickson B.A., Granieri M.A. et al. Stricture recurrence after urethroplasty: a systematic review. J Urol 2009;182(4):1266–70. DOI: 10.1016/j.juro.2009.06.027. PMID: 19683309.Herschorn S., Elliott S.P., Coburn M. et al. SIU/ICUD consultation on urethral strictures: posterior urethral stenosis after treatment of prostate cancer, Urology 2014;83(3 Suppl):S59–70. DOI: 10.1016/j.urology.2013.08.036. PMID: 24361008.Herschorn S., Elliott S.P., Coburn M. et al. SIU/ICUD consultation on urethral strictures: posterior urethral stenosis after treatment of prostate cancer, Urology 2014;83(3 Suppl):S59–70. DOI: 10.1016/j.urology.2013.08.036. PMID: 24361008.Sanda M.G., Dunn R.L., Michalski J. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250–61. DOI: 10.1056/NEJMoa074311. PMID: 18354103.Ficarra V., Novara G., Ahlering T.E. et al. Systematic review and meta-analysis of studies reporting potency rates after robotassisted radical prostatectomy. Eur Urol 2012;62(3):418–30. DOI: 10.1016/j.eururo.2012.05.046. PMID: 22749850.Incrocci L., Jensen P.T. Pelvic radiotherapy and sexual function in men and women. J Sex Med 2013;10(Suppl 1):53–64. DOI: 10.1111/jsm.12010. PMID: 23387912.Ellis D.S., Manny J., Rewcastle J.C. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 2007;70(6 Suppl):9–15. DOI: 10.1016/j.urology.2007.07.036. PMID: 18194712.Poissonnier L., Chapelon J.Y., Rouvière O. et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51(2):381–7. DOI: 10.1016/j.eururo.2006.04.012. PMID: 16857310.Merrick G.S., Wallner K.E., Butler W.M. Prostate cryotherapy: more questions than answers. Urology 2005;66(1):9–15. DOI: 10.1016/j.urology.2004.12.039. PMID: 15992870.Nehra A., Jackson G., Miner M. et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012;87(8):766–78. DOI: 10.1016/j.mayocp.2012.06.015. PMID: 22862865.Swearingen D., Nehra A., Morelos S., Peterson C.A. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context 2013;2013:212–48. DOI: 10.7573/dic.212248. PMID: 24432037.Yu Y.F., Nichol M.B., Yu A.P., Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 2005;8(4):495–505. DOI: 10.1111/j.1524-4733.2005.00041.x. PMID: 16091027.Kalder M., Pantazis K., Dinas K. et al. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol 2014;124(4):794–800. DOI: 10.1097/AOG.0000000000000468. PMID: 25198276.Kalder M., Pantazis K., Dinas K. et al. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol 2014;124(4):794–800. DOI: 10.1097/AOG.0000000000000468. PMID: 25198276.Coombs P.G., Heck M., Guhring P. et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int 2012;110(11):1787–91. DOI: 10.1111/j.1464-410X.2012.11080.x. PMID: 22564343.Coombs P.G., Heck M., Guhring P. et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int 2012;110(11):1787–91. DOI: 10.1111/j.1464-410X.2012.11080.x. PMID: 22564343.Porst H., Burnett A., Brock G. et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med 2013;10(1):130–71. DOI: 10.1111/jsm.12023. PMID: 23343170.Antonini G., Busetto G.M., De Berardinis E. et al. Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: Evaluation of efficacy, satisfaction profile and complications. Int J Impot Res 2016;28(1):4–8. DOI: 10.1038/ijir.2015.33. PMID: 26657316.Elliott S.P., McAninch J.W., Chi T. et al. Management of severe urethral complications of prostate cancer therapy. J Urol 2006;176(6 Pt 1):2508–13. DOI: 10.1016/j.juro.2006.07.152. PMID: 17085144.Walsh P.C., Partin A.W. Anatomic radical retropubic prostatectomy. In: Campbell-Walsh Urology. Saunders Elsevier, Philadelphia, Pa, USA, 9th edn, 2006.Noldus J., Fernandez S., Huland H. Rectourinary fistula repair using the Latzko technique. J Urol 1999;161(5):1518–20. PMID: 10210386.Bahn D.K., Lee F., Badalament R. et al.Targeted cryoablation of the prostate: 7-year outcomes in the primary treat ment of prostate cancer. Urology 2002;60(2 Suppl 1):3–11. PMID: 12206842.Mack D., Jungwirth A., Adam U. et al. Long-term follow-up after open perineal cryotherapy in patients with locally confined prostate cancer. Eur Urol 1997;32(2):129–32. PMID: 9286641.Mack D., Jungwirth A., Adam U. et al. Long-term follow-up after open perineal cryotherapy in patients with locally confined prostate cancer. Eur Urol 1997;32(2):129–32. PMID: 9286641.Thomas C., Jones J., Jager W. et al. Incidence, clinical symptoms and management of rectourethral fistulas after radical prostatectomy. J Urol 2010;183(2):608– 12. DOI: 10.1016/j.juro.2009.10.020. PMID: 20018317.dal Moro F., Mancini M., Pinto F. et al. Successful repair of latrogenic rectourinary fistulas using the posterior sagittal transrectal approach: 15-year experience. World J Surg 2006;30(1):107–13.Renschler T.D., Middleton R.G. 30 years of experience with York-Mason repair of recto-urinary fistulas. J Urol 2003; 170(4 Pt 1):1222–5. DOI: 10.1097/01.ju.0000082013.58783.17. PMID: 14501729.Renschler T.D., Middleton R.G. 30 years of experience with York-Mason repair of recto-urinary fistulas. J Urol 2003; 170(4 Pt 1):1222–5. DOI: 10.1097/01.ju.0000082013.58783.17. PMID: 14501729.